Abstract
Osteoarthritis (OA) constitutes a major health problem. Different signaling pathways are involved that impair homeostasis, but the cross-talk between them (although well investigated and partly understood), remains unclear. HIF-1α promotes chondrocyte differentiation and survival, while HIF-2α coactivates with β-catenin and NF-κB pathways to promote chondrocyte apoptosis and endochondral ossification. Depending on the ALK1/ALK5 ratio in chondrocytes, the TGFβ pathway can play an anabolic or catabolic role. TGFβ1 can activate the β-catenin signaling pathway via ALK5, Smad3, PI3K, and PKA pathways. The mediator Axins balance TGF-β and Wnt/β-catenin signaling during chondrocyte proliferation and maturation. However, the biological functions of Wnt/β-catenin signaling are still controversial. Both excessive and insufficient β-catenin levels may impair the homeostasis of articular chondrocytes by enhancing pathological maturation and apoptosis, respectively; loss- and gain-of-functions of β-catenin cause apoptosis at the center of the joint and chondrocyte maturation at the periphery, depending on the vascularity. The NF-κB transcription factor can be triggered by a host of stress-related stimuli including pro-inflammatory cytokines. The recent discovery of functional cross-regulation between these pathways has shown complex roles for HIF-1α/HIF-2α, TGFβ/BMP, Wnt/β-catenin, and NF-κB signaling pathways in the pathogenesis of OA. This has important implications for potential therapeutic agents directed at these pathways.
This review attempts to cover the literature of the past three years dealing with the biology and pathology of the HIF-1α/-2α, TGFβ/BMP, Wnt/β-catenin, and NF-κB/cytokines signaling pathways in OA.
Keywords: Osteoarthritis, HIF, TGFβ, Wnt/β-catenin, NF-κB, HIF-2α, β-catenin, Smad3, PI3K, PKA pathways
Current Pharmaceutical Design
Title:Insights on Biology and Pathology of HIF-1α/-2α, TGFβ/BMP, Wnt/β-Catenin, and NF-κB Pathways in Osteoarthritis
Volume: 18 Issue: 22
Author(s): Longhuo Wu, Xianhua Huang, Linfu Li, Hao Huang, Ruian Xu and Walter Luyten
Affiliation:
Keywords: Osteoarthritis, HIF, TGFβ, Wnt/β-catenin, NF-κB, HIF-2α, β-catenin, Smad3, PI3K, PKA pathways
Abstract: Osteoarthritis (OA) constitutes a major health problem. Different signaling pathways are involved that impair homeostasis, but the cross-talk between them (although well investigated and partly understood), remains unclear. HIF-1α promotes chondrocyte differentiation and survival, while HIF-2α coactivates with β-catenin and NF-κB pathways to promote chondrocyte apoptosis and endochondral ossification. Depending on the ALK1/ALK5 ratio in chondrocytes, the TGFβ pathway can play an anabolic or catabolic role. TGFβ1 can activate the β-catenin signaling pathway via ALK5, Smad3, PI3K, and PKA pathways. The mediator Axins balance TGF-β and Wnt/β-catenin signaling during chondrocyte proliferation and maturation. However, the biological functions of Wnt/β-catenin signaling are still controversial. Both excessive and insufficient β-catenin levels may impair the homeostasis of articular chondrocytes by enhancing pathological maturation and apoptosis, respectively; loss- and gain-of-functions of β-catenin cause apoptosis at the center of the joint and chondrocyte maturation at the periphery, depending on the vascularity. The NF-κB transcription factor can be triggered by a host of stress-related stimuli including pro-inflammatory cytokines. The recent discovery of functional cross-regulation between these pathways has shown complex roles for HIF-1α/HIF-2α, TGFβ/BMP, Wnt/β-catenin, and NF-κB signaling pathways in the pathogenesis of OA. This has important implications for potential therapeutic agents directed at these pathways.
This review attempts to cover the literature of the past three years dealing with the biology and pathology of the HIF-1α/-2α, TGFβ/BMP, Wnt/β-catenin, and NF-κB/cytokines signaling pathways in OA.
Export Options
About this article
Cite this article as:
Wu Longhuo, Huang Xianhua, Li Linfu, Huang Hao, Xu Ruian and Luyten Walter, Insights on Biology and Pathology of HIF-1α/-2α, TGFβ/BMP, Wnt/β-Catenin, and NF-κB Pathways in Osteoarthritis, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023293
DOI https://dx.doi.org/10.2174/1381612811209023293 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Editorial
Recent Patents on Inflammation & Allergy Drug Discovery RAS/RAF/MEK Inhibitors in Oncology
Current Medicinal Chemistry Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics
Current Signal Transduction Therapy Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Pancreatic Cancer Therapy (Guest Editor: Dr. Felix Ruckert)]
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy
Current Drug Targets Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry